14
NEWS
An update on Ascensia
Once again this year, Ascensia has
supported the Spare a Rose campaign
for the fifth year running. Spare
a Rose asks people to donate the
money they would otherwise spend
on roses for Valentine's Day to the
campaign which is run by members
of the diabetes community to raise
money for diabetes charities, and this
year it is in support of Insulin for Life.
Insulin for Life redistributes diabetes
supplies which would otherwise
go to waste to help save the lives
of people with diabetes in over 74
countries around the world. Ascensia
encouraged its 1,500 employees to
donate and will match their donations
up to one rose ($5) per employee, plus
an initial donation of $5,000.
Chris Aldred, a diabetes advocate
and blogger, said, "The success of
previous campaigns and the help
of corporate partners like Ascensia
have saved the lives of thousands
of children and young people in
underserved countries. Life for a
Child supports children and young
adults up to 26 years old. That's why
this year, as a community, we decided
to direct donations from the Spare a
Rose campaign to Insulin for Life to
extend our support there too."
Donations to Spare a Rose can be
made at www.sparearose.org.
Platform expands
Meanwhile in the UK, Ascensia
continues to roll out its GlucoContro.
online, a browser-based diabetes
management and analytics platform
that enables data driven care for
people using one of the meters in
the CONTOUR® blood glucose
monitoring portfolio. Through a
single platform, people with diabetes
(PWDs) can access their diabetes
data online and share it with their
healthcare providers (HCPs) and
caregivers through dedicated web
Apps.
Using GlucoContro.online makes
gathering, accessing and sharing
blood glucose data straightforward
for PWDs. The easy-to-use and
intuitive cloud-based platform,
opens directly in the browser and
provides a simple wizard for data
download. For those using one of the
connected meters in the Contour
portfolio it gathers data directly from
the ContourDiabetes app or Contour
Cloud. It also provides the option
for those not using a connected
meter to share their data via a cable,
which requires a simple single step
installation, with no forced restart
and the appropriate devices are
found automatically. Once the data
has been downloaded, the platform
allows users to conveniently view
data, generate reports and share
them across their care team.
For HCPs and caregivers,
GlucoContro.online allows them
to easily view data, such as blood
glucose measurements, insulin
dosing, food and activity by simply
opening a user profile on the
platform, once the user has granted
them permission.
In addition, the platform
incorporates industry leading
innovations and other features that
address some of the challenges and
concerns that HCPs and PWDs have
experienced with existing platforms.
These include the ability to instantly
onboard patients through QR codes
or a simple one-click invitation; the
option for PWDs to store data in their
own personal cloud drive or offline
storage; and the ability to generate
easy-to-read colour coded charts
and reports to speed up and make it
easier for HCPs to analyze the data,
alongside interactive aggregations or
groupings.
180 days
Ascensia Diabetes Care, a global
diabetes care company, announces
that its partner Senseonics Holdings,
Inc. has received approval from
the American Food and Drug
Administration (FDA) for the nextgeneration
Eversense E3 Continuous
Glucose Monitoring (CGM) System.
Ascensia plans to make the Eversense
E3 sensor, which can be used for up
to six months (180 days), available
to patients in the USA towards the
end of 2022. The Eversense CGM
System consists of an implanted
fluorescence-based sensor, a smart
transmitter worn over the sensor,
and a mobile app for displaying
glucose values, trends and alerts.
The transmitter can also be removed,
recharged and re-attached to
the skin without discarding the
sensor. The sensor is inserted
subcutaneously in the upper arm by a
health care provider. It requires fewer
calibrations than earlier models, with
primarily one calibration required per
day after day 21 of use.
Robert Schumm, President at
Ascensia Diabetes Care, said, "As the
world's first and only long-term CGM
System, Eversense is truly innovative
and the prospect of using a single
sensor for six months is a huge step
forward for people with diabetes.
Ensuring that as many people as
possible have access to Eversense
E3 is key for us. We look forward
to rolling out this next-generation
system through our dedicated CGM
commercial team in the US in the
coming months, as we strive to
improve the lives of people with
diabetes everywhere."
Mary Puncochar, Head of
Ascensia's Region US, commented,
"We hear from people living with
diabetes and their healthcare
providers how transformative
the Eversense system can be
in facilitating their diabetes
management. People using the
system appreciate how Eversense
provides discretion with a removable
transmitter, peace of mind through
the on-body alerts, and the freedom
that a longer-term sensor provides."
For more on Eversense,
CLICK HERE.